TOP NEWS: AstraZeneca, Daiichi hail datopotamab lung cancer trial

(Alliance News) - AstraZeneca PLC and Tokyo-based partner Daiichi Sankyo Co Ltd on Monday ...

Alliance News 3 July, 2023 | 7:42AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - AstraZeneca PLC and Tokyo-based partner Daiichi Sankyo Co Ltd on Monday announced that their investigational antibody drug conjugate Datopotamab deruxtecan showed positive results in an advanced non-small cell lung cancer trial.

The companies said the conjugate showed "statistically significant improvement for the dual primary endpoint of progression-free survival" when compared to docetaxel, the current standard of care chemotherapy.

However, for the dual primary endpoint of overall survival, data were not mature, but an early trend was observed in favour of the conjugate compared to docetaxel.

Susan Galbraith, executive vice president of AstraZeneca's Oncology research and development unit said: "These first phase III trial results from the datopotamab deruxtecan clinical programme provide compelling evidence for the potential role this TROP2-directed antibody drug conjugate can play in treating patients with lung cancer."

TROP2 is a protein highly expressed in a large majority of lung cancers.

AstraZeneca shares were down 5.1% to 10,702.00 pence each in London on Monday morning, while Daiichi Sankyo shares closed up 0.6% at JPY4,578.00 in Tokyo.

By Tom Budszus, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
AstraZeneca PLC 12,314.00 GBX -0.03
Daiichi Sankyo Co Ltd 5,415.00 JPY -0.13

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures